Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Federal Reserve shifts to quarter-point rate rise but warns of more to come
    • ‘Hybrid identities’: why Germany is updating its citizenship rules
    • ECB set to raise rates despite fall in eurozone inflation
    • Brussels urged to rein in Ukraine’s ‘unrealistic’ EU hopes
    • Italy to join forces with France in supplying air defences to Ukraine
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Adani sell-off tops $90bn as share sale fails to ease crisis
      • ‘Extreme leverage’? Adani’s debt-driven expansion under scrutiny
      • Adani Enterprises calls off $2.4bn share sale
      • Perella Weinberg banker tied to insider trading probe found dead
      • How First Abu Dhabi Bank pursued Standard Chartered and ‘opened Pandora’s box’
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news: FedEx to cut global leadership team by more than 10%
      • Adani Enterprises calls off $2.4bn share sale
      • Perella Weinberg banker tied to insider trading probe found dead
      • US stocks jump after Fed announces smaller rate rise
      • Lebanon devalues official exchange rate by 90%
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • End the Fed ‘put’
      • When good economic news may not be good news
      • The return of the ‘British disease’
      • Conservatives are too keen on money to win the culture war
      • Conservatives are forced to face the economic case for net zero
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Shoshana Zuboff: ‘Privacy has been extinguished. It is now a zombie’
      • A new generation refuses to keep quiet on age discrimination at work
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • The secrets of the Mercedes-Benz Holy Halls
      • Alexa Chung on the unpolished appeal of Indie Sleaze
      • Why I’m only buying five new things in 2023
      • Whitechapel Gallery offers thrilling landmark show of female abstract artists — review
      • Episode 3 of ‘The Last of Us’ shows TV at its best
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Merck & Co Inc

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Friday, 23 December, 2022
      LexDrugs research
      Medicines: triumph of science in 2022 is worth celebrating Premium content

      From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances

    • Thursday, 22 December, 2022
      Coronavirus treatment
      Merck antiviral trial shows promising impact on Covid recovery time

      Results of UK study show drug cuts symptom duration by about 4 days but does not reduce deaths

    • Tuesday, 13 December, 2022
      Drugs research
      Moderna’s mRNA cancer vaccine shows promise in early trial

      Study suggests combination with Merck immunotherapy drug reduces risk of death in high-risk patients

    • Thursday, 6 October, 2022
      Coronavirus treatment
      Merck Covid antiviral pill did not cut hospitalisation risk, study finds

      UK trial shows ‘no difference’ between taking molnupiravir or placebo in reducing clinical admissions during Omicron wave

    • Sunday, 7 August, 2022
      Pharmaceuticals sector
      Merck defends tax approach against senator’s claims of avoidance

      Chief financial officer says drugmaker complies with law amid congressional probe

    • Friday, 8 July, 2022
      Lex
      Merck/SeaGen: regulatory hurdles will be tough to clear Premium content

      Tie-up faces obstacles in current climate of aggressive watchdogs and concern over drug prices

    • Thursday, 7 July, 2022
      Pharmaceuticals sector
      Merck in talks over $40bn deal for cancer biotech SeaGen

      US group attracted by approved drugs as it prepares to lose patent protection of Keytruda

    • Wednesday, 16 February, 2022
      Coronavirus treatment
      Merck struggles to win European approval for Covid antiviral pill

      EMA said to be unlikely to grant marketing authorisation to molnupiravir this month after ‘problematic’ data

    • Wednesday, 22 December, 2021
      Covid-19 vaccines
      France cancels order for Merck antiviral tablet on efficacy fears

      Concerns grow over molnupiravir’s ability to reduce Covid hospitalisations and deaths

    • Sunday, 5 December, 2021
      Coronavirus treatment
      Merck takes aim at Pfizer’s Covid pill as concerns linger over its own drug

      Executive says patients on other medications will not be able to take competing antiviral treatment

    • Tuesday, 30 November, 2021
      Coronavirus treatment
      Merck’s Covid pill secures narrow backing from US regulatory panel

      Experts advising FDA recommend treatment for high-risk patients amid fears over Omicron variant

    • Friday, 26 November, 2021
      Coronavirus treatment
      Merck says its Covid antiviral treatment less effective than first thought

      Full analysis of trial results shows molnupiravir had a risk reduction of 30%

    • Friday, 12 November, 2021
      The Big Read
      The Covid drugs are finally here

      New medicines from Pfizer and Merck could take some pressure off hospitals. But will they work on the already vaccinated?

    • Thursday, 4 November, 2021
      Coronavirus treatment
      Merck’s Covid pill Lagevrio secures green light from UK regulator

      First authorisation for antiviral drug that halves risk of hospitalisation or death

    • Wednesday, 27 October, 2021
      Coronavirus treatment
      Merck signs royalty-free deal to expand access to its Covid-19 pill

      Move contrasts with mRNA makers Pfizer and Moderna, which have rejected sharing vaccine technology

    • Tuesday, 12 October, 2021
      LexCoronavirus treatment
      Coronavirus pill: Merck forges a new hammer to crack pandemic Premium content

      Molnupiravir has limitations but drugmakers should be able to build on it to create other treatments

    • Tuesday, 12 October, 2021
      Coronavirus treatment
      Merck aims to double supply of Covid-19 antiviral pill on rising demand

      Drugmaker seeks authorisation from FDA for oral treatment shown to prevent severe disease in vulnerable people

    • Wednesday, 6 October, 2021
      News in-depthPharmaceuticals sector
      Merck on deals hunt as patent cliff looms for top cancer drug

      Investors fret over how company will fare when Keytruda loses exclusivity

    • Friday, 1 October, 2021
      Coronavirus treatment
      Merck says Covid antiviral pill halves risk of hospitalisation and death

      US pharma group seeks authorisation for first drug of its kind after ‘remarkable’ clinical trial

    • Thursday, 30 September, 2021
      Merck to buy Acceleron Pharma for $11.5bn

      Acquisition will expand US pharmaceutical company’s pipeline of cardiovascular treatments

    • Thursday, 3 June, 2021
      Medical science
      AstraZeneca and Merck point to progress in fighting breast cancer

      Lynparza shown to reduce recurrence rates, while Novartis to unveil new type of radiotherapy

    • Wednesday, 10 March, 2021
      News in-depthFT Film24 min
      Covid-19 and the business of vaccines

      New vaccine producers and mRNA technology are shaking up the market

    • Tuesday, 2 March, 2021
      Covid-19 vaccines
      Biden says US will have enough jabs to vaccinate all adults by end of May

      White House announces accelerated timeline after brokering production deal between J&J and Merck

    • Friday, 26 February, 2021
      UK business & economy
      Cancer drug is first to begin fast-track UK approval process

      Approach seeks to cut years off traditional licensing process for treatments

    • Tuesday, 16 February, 2021
      News in-depthCovid-19 vaccines
      Why the three biggest vaccine makers failed on Covid-19

      GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In